ArticlePloS one2025
Anethole inhibits human U87 Glioma cell proliferation by inducing apoptosis via the PI3K/AKT pathway.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cytotoxic Dihydroagarofuran Sesquiterpenoids Isolated From the Roots of Tripterygium wilfordii.Chemistry & biodiversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma is characterized by rapid progression, resistance to conventional therapies, and poor prognosis. Current treatments are often limited by their inability to selectively target tumor cells. Natural compounds, such as anethole, have shown promising anticancer properties in various cancers, but their efficacy in glioblastoma remains unexplored. This study investigates the anticancer activity of anethole in glioma cells, focusing on its influence on cell proliferation, apoptosis, and the PI3K/Akt pathway. Human glioma cell lines (U87-MG and LN-229) and normal human astrocytes (NHA) were treated with anethole. Cell viability was evaluated using the CCK-8 assay, while colony formation and AO/EB staining assays evaluated proliferation and apoptosis, respectively. Cell viability was evaluated using the CCK-8 assay, while colony formation and AO/EB staining assessed proliferation and apoptosis, respectively. Western blotting was used to analyze apoptosis-related markers and PI3K/AKT pathway proteins. Molecular docking assessed anethole-PI3K binding, and in silico analyses (SwissTargetPrediction, KEGG, RummaGEO) identified putative targets and pathways. Anethole exhibited selective cytotoxicity, with significantly lower IC₅₀ values for U87-MG (10.8 ± 0.42 µM) and LN-229 (12.5 ± 0.51 µM) compared to NHA cells (61.5 ± 1.27 µM), calculated from three independent experiments with triplicate wells. Colony formation was notably inhibited in a dose-dependent manner. AO/EB staining and Western blotting confirmed this with upregulation of Bax, downregulation of Bcl-2, and reduced phosphorylation of PI3K and Akt. Molecular docking revealed strong binding affinity of anethole to PI3K (-9.32 kcal/mol), and Western blot showed inhibition of PI3K and Akt phosphorylation. Anethole selectively inhibits glioma cell proliferation by inducing apoptosis and suppressing the PI3K/Akt cascade. These observations underscore its potential as a novel therapeutic agent for glioblastoma, warranting further preclinical and clinical investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.